# Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

> **NCT02921984** · PHASE1 · COMPLETED · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 20 (actual)

## Conditions studied

- Salivary Gland Tumors
- Head and Neck Cancer

## Interventions

- **DRUG:** Docetaxel
- **RADIATION:** Intensity-modulated radiotherapy
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02921984
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921984, "Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02921984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*